Sznol M - Search Results

1

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS. Topalian SL, et al. Among authors: sznol m. J Clin Oncol. 2014 Apr 1;32(10):1020-30. doi: 10.1200/JCO.2013.53.0105. Epub 2014 Mar 3. J Clin Oncol. 2014. PMID: 24590637 Free PMC article. Corrected and republished. Clinical Trial.

2

Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2a in patients with metastatic melanoma. A phase II Study.

Sznol M, Steis RG, Smith JW 2nd, Janik JE, Sharfman WH, Urba WJ, Fenton RG, Creekmore SP, Beveridge J, Longo DL. Sznol M, et al. Online J Curr Clin Trials. 1992 Jul 1;Doc No 9:[3841 words; 32 paragraphs]. Online J Curr Clin Trials. 1992. PMID: 1343617 Clinical Trial.

3

Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.

Sznol M, Clark JW, Smith JW 2nd, Steis RG, Urba WJ, Rubinstein LV, VanderMolen LA, Janik J, Sharfman WH, Fenton RG, et al. Sznol M, et al. J Natl Cancer Inst. 1992 Jun 17;84(12):929-37. doi: 10.1093/jnci/84.12.929. J Natl Cancer Inst. 1992. PMID: 1629914

4

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.

Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, et al. Weiss GR, et al. Among authors: sznol m. J Clin Oncol. 1992 Feb;10(2):275-81. doi: 10.1200/JCO.1992.10.2.275. J Clin Oncol. 1992. PMID: 1732429 Clinical Trial.

5

Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma.

Margolin KA, Aronson FR, Sznol M, Atkins MB, Ciobanu N, Fisher RI, Weiss GR, Doroshow JH, Bar MH, Hawkins MJ, et al. Margolin KA, et al. Among authors: sznol m. J Immunother (1991). 1991 Jun;10(3):214-20. doi: 10.1097/00002371-199106000-00008. J Immunother (1991). 1991. PMID: 1868045 Clinical Trial.

6

A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.

Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, Sznol M, Mier J, Sparano J, Fisher RI, Weiss G, et al. Dutcher JP, et al. Among authors: sznol m. J Clin Oncol. 1991 Apr;9(4):641-8. doi: 10.1200/JCO.1991.9.4.641. J Clin Oncol. 1991. PMID: 2066760 Clinical Trial.

7

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.

Parkinson DR, Abrams JS, Wiernik PH, Rayner AA, Margolin KA, Van Echo DA, Sznol M, Dutcher JP, Aronson FR, Doroshow JH, et al. Parkinson DR, et al. Among authors: sznol m. J Clin Oncol. 1990 Oct;8(10):1650-6. doi: 10.1200/JCO.1990.8.10.1650. J Clin Oncol. 1990. PMID: 2213101 Clinical Trial.

8

Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.

Bar MH, Sznol M, Atkins MB, Ciobanu N, Micetich KC, Boldt DH, Margolin KA, Aronson FR, Rayner AA, Hawkins MJ, et al. Bar MH, et al. Among authors: sznol m. J Clin Oncol. 1990 Jul;8(7):1138-47. doi: 10.1200/JCO.1990.8.7.1138. J Clin Oncol. 1990. PMID: 2358835

9

A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma.

Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Margolin KA, Rayner AA, Sznol M, Parkinson DR, Paietta E, et al. Hawkins MJ, et al. Among authors: sznol m. J Immunother Emphasis Tumor Immunol. 1994 Jan;15(1):74-8. doi: 10.1097/00002371-199401000-00010. J Immunother Emphasis Tumor Immunol. 1994. PMID: 8110733 Clinical Trial.

10

Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma.

Margolin K, Aronson FR, Sznol M, Atkins MB, Gucalp R, Fisher RI, Sunderland M, Doroshow JH, Ernest ML, Mier JW, et al. Margolin K, et al. Among authors: sznol m. J Immunother Emphasis Tumor Immunol. 1994 Feb;15(2):147-53. doi: 10.1097/00002371-199402000-00009. J Immunother Emphasis Tumor Immunol. 1994. PMID: 8136948 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

240 results

Search Page